Replies to post #11344 on Pluristem Therapeutics Inc (PSTI)

[Spideyboy]

Sure,

I came to that conclusion as the yahoo article clearly stated:

"Citing a potential need for larger data sets, Credit Suisse pushed back its launch timeline estimates for Mesoblast's chronic heart failure and back pain therapies, which are in late-stage studies, by one to three years in the U.S. and by three to four years in regions outside the U.S., Young said in a Thursday note.@

So this was "Citing a potential need for larger data sets".

Now if you have been conducting a clinical trial with all the costs that have gone into it. And then near the end, it looks like you need a larger data set, then it would look like you didn't plan/design the trial well.

Thus poor trial design. They should have made sure to have the right design to ensure a data set that would have satisfied the stakeholders.

Because of this error, they are likely to need more money and time to start a lot of the process over again, thus the delay of up to 4 years, as mentioned in the quote from the article.